Dicerna Pharmaceuticals Inc has reached its limit for free report views.
Dicerna Pharmaceuticals Inc does not currently have any hardcopy reports on AnnualReports.com. Click the button below to request a report when hardcopies become available.
Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of treatments for liver diseases and cancers based on a proprietary RNA interference technology platform in the United States and internationally. The company’s development programs include DCR-PH1 for the treatment of primary hyperoxaluria type 1 (PH1) through targeting the gene encoding the liver enzyme glycolate oxidase; and other rare inherited diseases involving genes expressed in the liver.
